A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
about
Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formationA phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivoRAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.Drug monographs: belinostat and idelalisib.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerNew developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.Targeting Histone Deacetylases in Diseases: Where Are We?Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesRomidepsin: a novel histone deacetylase inhibitor for cancer.Belinostat: clinical applications in solid tumors and lymphoma.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.p53 acetylation enhances Taxol-induced apoptosis in human cancer cells.Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
P2860
Q28478040-5932F6B2-C378-407D-B979-D17325458881Q33399902-472B8570-3AD1-4E72-85FB-B309564CEB61Q33417499-5DDF8776-8D60-468D-BA21-4CBC9014F56EQ33418737-8A259073-63C6-4023-8E42-329356C8CF14Q33779854-2731CD1C-8036-4BEE-8EC7-58F0209815F7Q33927370-25E549DC-408A-41C9-8D84-C0AC55944968Q34008663-1E0C7AAB-32A2-499B-BDE4-84EC8DDA0AAEQ34645445-86505CD9-E076-425C-A084-D9419C0B5E6CQ35025521-1CD4A6A1-A8B4-4D72-AD18-741E0096D254Q35057942-03E637EC-2B52-449A-8E00-2DF04F6158D6Q35079955-919E141E-E080-403A-997F-56403E9D547AQ35703714-8313D462-5821-4E6A-9A44-3C67595EADBDQ35821728-22CB0A85-7059-4B22-808B-12B06C8A6AA1Q36023863-E2552064-2634-4051-B697-C7BF5D24D9C8Q36064937-67432888-8F15-43CB-805E-3943684AA9D6Q36654454-B296829A-1D02-45FE-BFC9-3326F426A2F7Q37226511-D1866DA7-E62A-41EE-92B3-2C7B3A7B4E96Q37893664-0CECA008-653A-461B-8954-C7608AA12524Q37951994-3BDC2708-9D42-4524-8B9E-E5D90DBA8689Q37993586-5533D43F-5BAB-4928-A8D4-0B74C13A34C9Q38012499-D49104F7-721A-4003-9326-5B248717E069Q38344675-7E465977-68B2-4E12-94C0-3FB162206EA7Q38735639-0FC8104C-2D4D-4E77-8972-BF8ACFD6EE60Q39051716-317323D8-82D4-4FFD-BB0A-C5AD13891FE8Q39242999-798C5546-E8A4-480D-AFBE-50D2992351CAQ39369865-22BD7393-750D-45BF-8E5D-99A558C3D71BQ44932310-AC85AACB-DA04-4968-8F19-EEAC05D0D358Q47393027-755F080F-CC6E-44F2-8B14-E597D9486199Q50546142-F34DDBD3-1B68-494B-9B4A-5F35D261D6DAQ52590685-D74958D7-8A01-4C1E-9168-D290F8989C9F
P2860
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A phase I study of the safety ...... in patients with solid tumours
@ast
A phase I study of the safety ...... in patients with solid tumours
@en
type
label
A phase I study of the safety ...... in patients with solid tumours
@ast
A phase I study of the safety ...... in patients with solid tumours
@en
prefLabel
A phase I study of the safety ...... in patients with solid tumours
@ast
A phase I study of the safety ...... in patients with solid tumours
@en
P2093
P2860
P356
P1476
A phase I study of the safety ...... in patients with solid tumours
@en
P2093
J S de Bono
J Tjornelund
L R Molife
P Buhl-Jensen
P Knoblauch
R T Penson
S-A Engelholm
P2860
P2888
P356
10.1038/SJ.BJC.6605726
P407
P577
2010-06-15T00:00:00Z
P5875
P6179
1007861836